DECIPHER
LABS LIMITED
Formerly Combat Drugs Limited

Regd.Off: A-2, Q2, 5th Floor, Cyber Towers, Hitech City, Madhapur, Hyderabad, Shaikpet, Telangana, India, 500081
Ph: (+91)-40-48536100 Url: www.decipherlabs.in Mail: decipherlabsltd@gmail.com
D.L No. TG/15/04/2016-14766/14767 CINNo.L24230TG1986PLC006781 GST:36AAACC8372L1ZB

Date: 13.08.2026

To,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001

Dear Sir/ Madam,

Unit: Decipher Labs Limited (Scrip Code: 524752)

Sub: Outcome of Board Meeting held on 13.08.2026

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Decipher Labs Limited** at its meeting held on Thursday, the 13th day of August, 2026 at 02:30 p.m. at registered office of the Company for the quarter ended 30th June, 2026 considered and approved the following:

1. Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026**. (Attached)**

2. Limited Review Report (Standalone and Consolidated) for the quarter ended 30th June, 2026. **(Attached)**

3. Appointment of Mr. Bhupendralal Waghray (DIN - 07337149) as an Additional Director (Independent Category) of the Company for a period of Five (5) years w.e.f. 13.08.2026, subject to approval of members in the ensuing General Meeting. **(Details are annexed as Attached A)**

The meeting concluded at 04:30 P.M.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Faithfully
For Decipher Labs Limited

DALAVATH AMAR SINGH
Digitally signed by DALAVATH AMAR SINGH
Date: 2026.08.13 17:06:52 +05'30'

Dalavath Amarsingh
Whole Time Director
(DIN: 02206249)

Annexure – A

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular SEBI/HO/CFD/PoD-2/P/CIR/2026/1 dated January 30, 2026)]

S. No	Particulars	Mr. Bhupendralal Waghray
1.	**Reason for change viz. appointment, resignation, removal, death or otherwise**	Appointment of Mr. Bhupendralal Waghray as an Additional Director (Independent Category) of Decipher Labs Limited.
2.	**Date of Appointment/ cessation (as applicable) & term of Appointment**	**Date of Appointment:** 13.08.2026 **Terms of Appointment:** Appointed for the period of Five (5) year(s), subject to the approval of shareholders.
3.	**Brief profile (in case of appointment)**	A seasoned government officer with 38 years of service in the Commercial Tax Department, Government of Andhra Pradesh, having served as a Deputy Commercial Tax Officer with extensive experience in tax administration and revenue matters.
4.	**Disclosure of relationships between directors (in case of appointment of a director)**	Not Applicable
5.	**Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no NSE/CML/2018/24 dated June 20, 2018**	Mr. Bhupendralal Waghray is not debarred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.

DECIPHER LABS LIMITED. (CIN L24230TG1986PLC006781)

Regd.off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040 29323151

Statement of Unaudited Standalone Financial Results For the Quarter Ended 30th June, 2026

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Year ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	9.81	6.69	84.65	113.54
II. Other income	-	0.11	-	0.13
III.Total Income (I + II)	**9.81**	**6.80**	**84.65**	**113.67**
IV. Expenses				
Purchase of Stock in trade	-	0.40	64.10	64.50
Changes in inventories of finished goods	0.40	(0.40)	-	(0.40)
Employee Benefits Expense	5.49	5.32	3.85	17.53
Depreciation expense	0.45	0.45	0.45	1.80
Other expenses	11.35	18.39	10.22	54.08
Total expenses	**17.69**	**24.15**	**78.62**	**137.51**
V. Profit/(Loss) before Exceptional items (III - IV)	(7.88)	(17.35)	6.03	(23.84)
VI. Exceptional items	-	-	-	-
VII. Profit/(Loss) after Exceptional items (V - VI)	**(7.88)**	**(17.35)**	**6.03**	**(23.84)**
VIII. Tax expense:				
(1) Current tax	-	-	-	-
(2) Deferred tax	0.04	(0.04)	0.44	0.85
IX. Profit/(Loss) for the period (VII-VIII)	**(7.93)**	**(17.31)**	**5.59**	**(24.68)**
X. Other comprehensive income	-	-	-	-
XI. Total comprehensive income for the year	**(7.93)**	**(17.31)**	**5.59**	**(24.68)**
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00
XII. Earning per equity share				
(1) Basic	(0.08)	(0.17)	0.06	(0.24)
(2) Diluted	(0.08)	(0.17)	0.06	(0.24)

Notes

1. The operations of the Company relate to two segments viz:, Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Year Ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue				
a) Manufacturing and Trading of Pharmaceutical drugs	0.40	-	67.50	67.50
b) Consultancy Services	9.41	6.69	17.15	46.04
Total Sales	**9.81**	**6.69**	**84.65**	**113.54**
Less: Inter Segment Revenue	-	-	-	
Total Revenue from Operations	**9.81**	**6.69**	**84.65**	**113.54**
Segment Result (Profit Before Tax and Interest from each Segment)				
a) Manufacturing and Trading of Pharmaceutical drugs	(0.32)	(10.07)	4.81	(14.17)
b) Consultancy Services	(7.56)	(7.28)	1.22	(9.66)
Total	**(7.88)**	**(17.35)**	**6.03**	**(23.83)**
Less: Interest and exceptional items	-	-	-	-
Total Profit before tax	**(7.88)**	**(17.35)**	**6.03**	**(23.83)**
Capital employed (Segment assets - segment liabilities)				
Segment assets				
a) Manufacturing and trading of Pharmaceutical drugs	902.14	899.52	999.00	899.23
b) Consultancy Services	5.20	-	4.28	-
Total Assets	**907.34**	**899.52**	**1,003.28**	**899.23**
Segment liabilities				
a) Manufacturing and trading of Pharmaceutical drugs	91.21	75.47	148.96	75.47
b) Consultancy Services	-	-	-	-
c) Unallocated liabilities	-	-	-	-
Total Liabilities	**91.21**	**75.47**	**148.96**	**75.47**

2. The above results for the quarter ended 30th June 2026 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13th Aug 2026.

3. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure

4. The Government of India has notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes") - consolidating 29 existing labour laws.

The New Labour Codes are effective from November 21, 2025. The Company has estimated no liability for own employees and is in the process of evaluating other possible impacts including for contract workforce.

For and on behalf of the Board

DECIPHER LABS LIMITED Hyderabad

Amar Singh Dalavath
Whole Time Director
DIN: 02206249

Place: Hyderabad
Date: 13.08.2026

DECIPHER LABS LIMITED. (CIN L24230TG1986PLC006781)

Regd.off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081
URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040 29323151

Statement of Unaudited Consolidated Financial Results For the Quarter Ended June 30, 2026

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter Ended			Year Ended
	30.06.2026	31.03.2026	30.06.2025	31st March, 2026
	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	241.39	360.40	292.37	1,405.40
II. Other income	9.75	17.37	1.12	22.09
III.Total revenue (I + II)	**251.13**	**377.77**	**293.49**	**1,427.49**
IV. Expenses				
Purchase of Stock-in-Trade	-	0.40	64.10	64.50
Changes in inventories of finished goods	0.40	(0.40)	-	(0.40)
Employee benefits expense	275.96	267.82	472.61	1,498.67
Depreciation and amortisation expense	12.89	14.86	11.71	51.63
Other expenses	180.40	69.93	87.30	181.58
Total expenses	**469.66**	**352.61**	**635.72**	**1,795.98**
V. Profit/(Loss) before Exceptional item (III - IV)	**(218.52)**	**25.16**	**(342.23)**	**(368.49)**
VI.Exceptional items	-	-	-	-
VII. Profit/(Loss) before tax (III - IV)	**(218.52)**	**25.16**	**(342.23)**	**(368.49)**
VIII. Tax expense:				
(1) Current tax	-	-	-	-
(2) Deferred tax	0.04	(60.95)	0.44	(60.06)
IX. Profit/(Loss) for the period (V-VI)	**(218.57)**	**(35.79)**	**(342.67)**	**(308.43)**
X. Other comprehensive income				
Items that will be reclassified to statement of profit and loss	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	25.46	88.55	28.45	89.37
XI. Total comprehensive income for the year	**(193.11)**	**52.76**	**(314.22)**	**(219.06)**
Net Profit/(Loss) for the year attributable to:				
Owners of the parent	(218.57)	86.11	(342.67)	(308.43)
Non-Controlling Interests	-	-	-	-
Other Comprehensive Income attributable to:				
Owners of the parent	25.46	88.55	28.45	89.37
Non-Controlling Interests	-	-	-	-
Total Comprehensive Income attributable to:				
Owners of the parent	(193.11)	174.66	(314.22)	**(219.06)**
Non-Controlling Interests	-	-	-	-
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00
Director				
(1) Basic	(2.16)	(0.35)	(3.39)	(3.05)
(2) Diluted	(2.16)	(0.35)	(3.39)	(3.05)

Notes

1. The operations of the Group relate to two segments viz:, Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter Ended			Year Ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue				
a) Manufacturing and Trading of Pharmaceutical drugs	(67.10)	-	67.50	67.50
b) Consultancy Services	(736.51)	360.40	224.87	1,337.90
Total Sales	**(803.61)**	**360.40**	**292.37**	**1,405.40**
Less: Inter Segment Revenue	-	-	-	-
Total Revenue from Operations	**(803.61)**	**360.40**	**292.37**	**1,405.40**
Segment Result (Profit Before Tax and Interest from each Segment)				
a) Manufacturing and Trading of Pharmaceutical drugs	25.07	7.73	4.80	(17.70)
b) Consultancy Services	150.07	17.44	(347.03)	(350.79)
Total	**175.14**	**25.17**	**(342.23)**	**(368.49)**
Less: Interest and exceptional item	-	-	-	-
Total Profit/(Loss) before tax	**175.14**	**25.17**	**(342.23)**	**(368.49)**
Capital employed (Segment assets - segment liabilities)				
Segment assets				
a) Manufacturing and trading of Pharmaceutical drugs	913.55	913.55	999.00	913.55
b) Consultancy Services	1,411.82	1,519.54	1,370.72	1,519.54
Total Assets	**2,325.37**	**2,433.09**	**2,369.72**	**2,433.09**
Segment liabilities				
a) Manufacturing and trading of Pharmaceutical drugs	75.47	75.47	148.96	75.47
b) Consultancy Services	376.49	291.11	346.53	291.11
Total Liabilities	**451.96**	**366.58**	**495.49**	**366.58**

2. The above results for the quarter ended 30th June 2026 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13th August 2026.

3. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements),

4. The above results as of 30th June 2026 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA and step down subsidiary Decipher W.L.L., Barhain.

5. The Government of India has notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes") - consolidating 29 existing labour laws.
The New Labour Codes are effective from November 21, 2025. The Company has estimated no liability for own employees and is in the process of evaluating other possible impacts including for contract workforce.

For and on behalf of the Board

DECIPHER LABS LIMITED
Hyderabad

Amar Singh Dalavath
Whole Time Director
DIN: 02206249

Place: Hyderabad
Date: 13.08.2026

Ramanatham & Rao
Chartered Accountants

P.B. No. 2102, Flat # 302, Kala Mansion,
Sarojini Devi Road, Secunderabad - 500 003
E-mail : ramanathamandrao@gmail.com
Phone : 27814147, 27849305, 27840307

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Decipher labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to
The Board of Directors
Decipher labs Limited.

1. We have reviewed the accompanying statement of unaudited standalone financial results of Decipher labs Limited (the "Company") for the quarter ended 30th June 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.002934S)

K. Sreenivasan
Partner
Membership No.206421

UDIN: **26206421JYLMVP5914**
Place: Secunderabad
Date : 13.08.2026

RAMANATHAM & RAO
Chartered Accontants
SEC'BAD

Ramanatham & Rao
Chartered Accountants
P.B. No. 2102, Flat # 302, Kala Mansion,
Sarojini Devi Road, Secunderabad - 500 003
E-mail : ramanathamandrao@gmail.com
Phone : 27814147, 27849305, 27840307

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Decipher labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial Results of Decipher labs Limited ("the Holding Company") and its subsidiaries, (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2026 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes the results of the subsidiaries.
   Decipher Software Solutions LLC, USA
   Decipher Soft Middle East W.L.L Bahrain

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiary referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

RAMANATHAM & RAO
Chartered Accountants
SEC'BAD

6. We did not review the interim financial results of one subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain included in the consolidated unaudited financial results whose interim financial results reflect total revenue of Rs.231.58 lakhs, total net profit/(loss) after tax of Rs. (210.64) lakhs and total comprehensive Income of Rs. (185.18) lakhs for the quarter ended 30th June 2026, as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of this subsidiary is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.002934S)

K.Sreenivasan
Partner
Membership No.206421

UDIN: **26206421JCQCWT8893**

Place : Secunderabad
Date : 13.08.2026

RAMANATHAM & RAO
Chartered Accontants
SEC'BAD